FIELD: chemistry.
SUBSTANCE: invention relates to hydrate compound of formula I, where R is H or cation, capable of forming a pharmaceutically acceptable salt, wherein water content in hydrate ranges from 8 to 30 wt%. Hydrate has high stability.
EFFECT: invention also describes a method of producing said hydrate and use thereof.
11 cl, 7 dwg, 16 ex
Title | Year | Author | Number |
---|---|---|---|
HIGH PURITY CYCLOPEPTIDE COMPOUND AS WELL AS PREPARATION METHOD AND USE THEREOF | 2013 |
|
RU2603345C2 |
HIGH-PURITY CYCLOPEPTIDE CRYSTAL AS WELL AS PREPARATION METHOD AND USE THEREOF | 2013 |
|
RU2607083C2 |
METHOD FOR OBTAINING AZETIDINONE COMPOUNDS AND DERIVATIVES OF AZETIDINONE COMPOUNDS | 2015 |
|
RU2650687C1 |
METHOD OF PURIFYING CYCLOPEPTIDE COMPOUNDS OR SALTS THEREOF | 2011 |
|
RU2538274C2 |
METHOD OF PURIFYING CYCLOPOLYPEPTIDE COMPOUNDS OR SALTS THEREOF | 2011 |
|
RU2535489C1 |
PYRIMIDINE COMPOUND AND METHOD FOR ITS PRODUCTION | 2020 |
|
RU2790017C1 |
METHODS FOR OBTAINING 5-[2-[7-(TRIFLUOROMETHYL)-5-[4-(TRIFLUOROMETHYL)PHENYL]PYRAZOLO[1,5-a]PYRIMIDINE-3-YL]ETHINYL]-2-PYRIDINAMINE | 2012 |
|
RU2630700C2 |
METHOD FOR OBTAINING PRAZIQUANTEL AND ITS INTERMEDIATE COMPOUNDS | 2015 |
|
RU2671202C1 |
METHODS AND INTERMEDIATES IN PRODUCING C5aR ANTAGONISTS | 2015 |
|
RU2712233C2 |
COMPOUND AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF | 2020 |
|
RU2819762C1 |
Authors
Dates
2016-08-20—Published
2013-03-29—Filed